Abstract : The use of AMH level in predicting outcomes of in-vitro fertilization/intra cytoplasmic sperm injection in poor responder women has been widely used. Since the term “poor responder” of Bologna criteria has been changed to "low prognosis" according to the POSEIDON (Patient-Oriented Strategies Encompassing IndividualizeD Oocyte Number) criteria, which divided low prognosis into 4 groups, therefore these studies aim to evaluate serum AMH levels in the group suspected of low prognosis women treated with IVF/ICSI. A total of 252 patients of suspected low prognosis groups were assessed retrospectively between 2018 and 2019 in Morula Clinic, National Hospital, Surabaya, Indonesia. Serum AMH cut off values determined for low prognosis groups. Serum AMH levels and pregnancy rate were compared among 4 subgroups of suspected low prognosis women treated IVF/ICSI. In this study, the serum AMH cut off value for predicting low prognosis women using POSEIDON criteria was 1.7 ng/mL with sensitivity 86.7% and specificity 70%. The serum AMH levels were significantly difference in 4 subgroups of suspected low prognosis women treated IVF/ICSI (p<0.05). Interestingly, there were no differences in pregnancy rate among those groups. In conclusion, serum AMH level could predict low prognosis women treated IVF/ICSI. It is important to determine cut-off value to predict the low prognosis women. The pregnancy rate among low prognosis subgroups was not difference.